Key Investor Signals
Shipped on iOS and Android within 11 months of incorporation
Incorporated in September 2025, CoRare released its iOS app in May 2026 and its Android app by August, putting the product on both major mobile platforms within 11 months.
Started onboarding its first rare-cardiac patient cohorts
After launch, CoRare said it was onboarding people with rare cardiac conditions alongside patient charities, clinical teams and research partners.
Selected for DigitalHealth.London’s NHS-focused Launchpad
The programme supports early-stage digital-health companies preparing high-potential products for NHS and social-care adoption.
Other Positive Signals
- Supported through Innovate UK’s Growth Catalyst, a UK government innovation programme.
- CEO Saadiq Moledina was selected for EWOR’s 10-person Ideation Fellowship cohort in 2024.
Team
Dr Saadiq Moledina
CEO and Co-founder
- Practising NHS doctor and senior cardiology registrar, with frontline experience in cardiovascular disease and patient care.
- PhD in epidemiology from the University of Cambridge, focused on inequalities in heart-disease care.
- Author of 35+ medical publications spanning cardiovascular disease, epidemiology and health inequalities.
Dr Jonathan Koß
CPO and Co-founder
- Previously co-founded NewsButler and served as CEO, building AI software for automated content delivery.
- Growth & Product Lead at Thryve, working on infrastructure for wearable health-data integration.
- PhD in economics, with peer-reviewed research on social-media mining for patient-centred drug development.
Philippe N'Techobo
CTO and Co-founder
- Former Coinbase Staff Software Engineer and founding engineer in its Stablecoin organisation.
- Former Lead AI Research Scientist at Cerence, working on conversational and language-based systems.
- Previously an AI researcher at Nuance, with a research background in natural-language processing.
Product
CoRare's mobile app combines condition-specific peer communities, symptom tracking and Kora, an educational AI assistant. It also captures patient-reported data over time, with consent, to support registries, research and clinical-trial recruitment.
Verified rare-disease communities
Users join verified, condition-specific communities, connect with people living with similar rare diseases, and communicate through feeds and direct chat for ongoing peer support.
Symptom and trigger tracking
Users can log symptoms, wellbeing, medications and possible triggers over time, creating a structured history that can reveal patterns between clinical visits.
Curated rare-disease AI guidance
Kora answers questions using curated educational content from medical experts and patient organisations. It provides orientation and information, not diagnosis or treatment advice.
Market Overview
Rare diseases are individually uncommon but collectively affect more than 3.5 million people in the UK. Diagnosis can take years, while patients are dispersed across thousands of conditions and locations, making specialist coordination and consistent evidence collection unusually difficult.
This fragmentation creates demand for tools that keep rare-disease patients engaged between visits and organise consented longitudinal data for registries, research and trials. The global patient-registry software market was estimated at $2.25 billion in 2025, providing a commercial benchmark for this infrastructure.
Estimated number of people in the UK living with a rare disease.
Reported average time from first symptoms to an accurate diagnosis.
Estimated global market for software supporting patient registries and real-world evidence.
Share of rare diseases currently estimated to have an approved treatment.
Comparable Outcomes
Flatiron Health
Flatiron built oncology electronic-health-record software and curated real-world datasets used by care providers and researchers. Roche completed its $1.9 billion acquisition of Flatiron Health in April 2018.
Propeller Health
Propeller combined connected inhaler sensors and software to collect medication-use data from patients outside clinical settings. ResMed acquired Propeller Health for $225 million in January 2019, adding a platform built around continuous patient-generated data.
Interested in More Startups Like CoRare?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.